Swipe Bills

Brand-name biologic drug makers would face a cap on how many patents they can use to sue companies seeking to sell cheaper biosimilar versions.

• Applies when the biosimilar maker completes certain steps, such as sharing product information with the biologic maker
• Limits certain patents, such as those filed more than four years after the original drug got market approval
• Does not limit patents claiming certain methods for using the biologic drug

Consumer products containing sodium nitrite at a concentration of 10% or greater would become banned hazardous products.

• Covers any consumer product with sodium nitrite at 10% or greater
• Exempts specified drugs, medical devices, cosmetics and food products